CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 139 enrolled
Drug / intervention
RRx-001 +11 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02489903
NCT02489903Phase 2Completed
CompareCT.gov

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.·interventional·Posted Jul 3, 2015·Updated Mar 17, 2025

In Brief

A Phase 2 clinical trial evaluating RRx-001, Cisplatin, and 10 other interventions for Small Cell Carcinoma and 3 related conditions. Completed, enrolled 139 participants across 10 sites.

Detailed Summary

This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 3, 2015
Enrollment StartJun 1, 2015
Primary CompletionDec 6, 2021
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 11.0 years ago

Interventions

RRx-001drug

Cisplatindrug

Etoposidedrug

Carboplatindrug

Irinotecandrug

Vinorelbinedrug

Doxildrug

Gemcitabinedrug

Taxanedrug

Paclitaxeldrug

Nab-Paclitaxeldrug

Pemetrexeddrug